MA32776B1 - Inhibiteurs de l'akt et de la p70 s6 kinase - Google Patents

Inhibiteurs de l'akt et de la p70 s6 kinase

Info

Publication number
MA32776B1
MA32776B1 MA33822A MA33822A MA32776B1 MA 32776 B1 MA32776 B1 MA 32776B1 MA 33822 A MA33822 A MA 33822A MA 33822 A MA33822 A MA 33822A MA 32776 B1 MA32776 B1 MA 32776B1
Authority
MA
Morocco
Prior art keywords
inhibitors
akt
kinase
formula
compounds
Prior art date
Application number
MA33822A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA32776B1 publication Critical patent/MA32776B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA33822A 2008-11-11 2011-05-09 Inhibiteurs de l'akt et de la p70 s6 kinase MA32776B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
PCT/US2009/063020 WO2010056563A1 (en) 2008-11-11 2009-11-03 Akt and p70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
MA32776B1 true MA32776B1 (fr) 2011-11-01

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33822A MA32776B1 (fr) 2008-11-11 2011-05-09 Inhibiteurs de l'akt et de la p70 s6 kinase

Country Status (36)

Country Link
US (1) US8148387B2 (enExample)
EP (1) EP2358710B1 (enExample)
JP (1) JP5432275B2 (enExample)
KR (1) KR101334460B1 (enExample)
CN (1) CN102216302B (enExample)
AR (1) AR074072A1 (enExample)
AU (1) AU2009314324B2 (enExample)
BR (1) BRPI0921916A2 (enExample)
CA (1) CA2743019C (enExample)
CO (1) CO6382114A2 (enExample)
CR (1) CR20110240A (enExample)
CY (1) CY1113409T1 (enExample)
DK (1) DK2358710T3 (enExample)
DO (1) DOP2011000129A (enExample)
EA (1) EA018947B1 (enExample)
EC (1) ECSP11011048A (enExample)
ES (1) ES2391704T3 (enExample)
HN (1) HN2011001247A (enExample)
HR (1) HRP20120738T1 (enExample)
IL (1) IL211940A (enExample)
JO (1) JO2822B1 (enExample)
MA (1) MA32776B1 (enExample)
MX (1) MX2011005000A (enExample)
MY (1) MY161461A (enExample)
NZ (1) NZ592062A (enExample)
PA (1) PA8846901A1 (enExample)
PE (1) PE20110807A1 (enExample)
PL (1) PL2358710T3 (enExample)
PT (1) PT2358710E (enExample)
RS (1) RS52520B (enExample)
SI (1) SI2358710T1 (enExample)
TN (1) TN2011000207A1 (enExample)
TW (1) TWI422587B (enExample)
UA (1) UA100190C2 (enExample)
WO (1) WO2010056563A1 (enExample)
ZA (1) ZA201102549B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120640A1 (es) 2009-07-02 2012-06-09 Sanofi Sa Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
MX336865B (es) 2011-04-07 2016-02-04 Bayer Pharma AG Imidazopiridazinas como inhibidores de quinasa akt.
ES2547687T3 (es) * 2011-07-09 2015-10-08 Xuanzhu Pharma Co., Ltd. Forma cristalina I de sal de un inhibidor de dipeptidil-peptidasa IV y procedimiento de preparación y uso de la misma
ES2646759T3 (es) 2011-09-12 2017-12-15 Merck Patent Gmbh Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa
HRP20171554T1 (hr) 2011-09-12 2017-11-17 Merck Patent Gmbh Novi imidazol amini kao modulatori aktivnosti kinaze
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
AR093511A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
MX370448B (es) * 2013-03-11 2019-12-13 Merck Patent Gmbh Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
JP6560243B2 (ja) * 2014-02-11 2019-08-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung キナーゼ活性のモジュレーターとしてのピリミジンイミダゾールアミン
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
JP6576553B2 (ja) * 2016-05-20 2019-09-18 大鵬薬品工業株式会社 新規5H−ピロロ[2,3−d]ピリミジン−6(7H)−オン誘導体
JP2023520140A (ja) * 2020-03-17 2023-05-16 江蘇恒瑞医薬股▲ふん▼有限公司 縮合二環系誘導体、その調製方法及びその医薬的応用
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3231865A1 (en) 2021-09-17 2023-03-23 Tingting SHANG Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor
MA71401A (fr) * 2022-07-05 2025-04-30 Taiho Pharmaceutical Co., Ltd. 5h-pyrrolo[2,3-d]pyrimidine-6(7h)-one, et cristaux de sel de celui-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
ES2391704T3 (es) 2012-11-29
SI2358710T1 (sl) 2012-11-30
BRPI0921916A2 (pt) 2015-12-29
AR074072A1 (es) 2010-12-22
PL2358710T3 (pl) 2012-12-31
ECSP11011048A (es) 2011-06-30
CN102216302A (zh) 2011-10-12
KR20110074578A (ko) 2011-06-30
TWI422587B (zh) 2014-01-11
US20100120801A1 (en) 2010-05-13
PE20110807A1 (es) 2011-10-31
MX2011005000A (es) 2011-05-25
EP2358710B1 (en) 2012-08-15
JP2012508274A (ja) 2012-04-05
EP2358710A1 (en) 2011-08-24
CY1113409T1 (el) 2016-06-22
MY161461A (en) 2017-04-14
PA8846901A1 (es) 2010-06-28
RS52520B (sr) 2013-04-30
NZ592062A (en) 2013-03-28
UA100190C2 (en) 2012-11-26
JO2822B1 (en) 2014-09-15
KR101334460B1 (ko) 2013-12-02
IL211940A0 (en) 2011-06-30
AU2009314324A1 (en) 2010-05-20
WO2010056563A1 (en) 2010-05-20
ZA201102549B (en) 2012-09-26
TN2011000207A1 (en) 2012-12-17
AU2009314324B2 (en) 2013-06-20
HK1158203A1 (en) 2012-07-13
HRP20120738T1 (hr) 2012-10-31
EA018947B1 (ru) 2013-11-29
CN102216302B (zh) 2013-08-21
IL211940A (en) 2014-01-30
JP5432275B2 (ja) 2014-03-05
DOP2011000129A (es) 2016-02-29
US8148387B2 (en) 2012-04-03
DK2358710T3 (da) 2012-09-03
CR20110240A (es) 2011-06-09
EA201170680A1 (ru) 2011-12-30
CA2743019C (en) 2013-08-13
PT2358710E (pt) 2012-10-01
CA2743019A1 (en) 2010-05-20
TW201022268A (en) 2010-06-16
CO6382114A2 (es) 2012-02-15
HN2011001247A (es) 2013-05-20

Similar Documents

Publication Publication Date Title
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY161461A (en) Akt and p70 s6 kinase inhibitors
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY153915A (en) Organic compounds
MY148634A (en) Pyridazinone derivatives
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
GEP20125652B (en) cMET INHIBITORS
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
UA94129C2 (ru) Соединения для ингибирования митоза
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
EA201170832A1 (ru) Пуриновые соединения
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
MX2012004780A (es) Inhibidores de akt.
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
TN2010000074A1 (en) Cyclic depsipeptides
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
SG158091A1 (en) Imidazoazepinone compounds
ATE502935T1 (de) C-met-proteinkinasehemmer
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
TW200745122A (en) New compounds I